Home Stock

Stock Research: 10x Genomics

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

10x Genomics

NSQ:TXG US88025U1097
31
  • Value
    48
  • Growth
    73
  • Safety
    Safety
    26
  • Combined
    49
  • Sentiment
    23
  • 360° View
    360° View
    31
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

10x Genomics, Inc. is a life science technology company providing integrated solutions for single cell and spatial biology. Its main businesses include instruments, consumables, and software for Chromium and Visium platforms, supporting single cell gene expression, immune profiling, ATAC, and spatial gene expression. The company operates globally. In the last fiscal year, the company had a market cap of $1,533 million, profits of $415 million, revenue of $611 million, and 1,306 employees.

more

ANALYSIS: With an Obermatt 360° View of 31 (better than 31% compared with alternatives), overall professional sentiment and financial characteristics for the stock 10x Genomics are below the industry average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for 10x Genomics. The consolidated Growth Rank has a good rank of 73, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. It ranks higher than 73% of competitors in the same industry. The other indicators are below average, namely the Value, Safety, and Sentiment Ranks.The Value Rank at 48 means that the share price of 10x Genomics is on the high side compared with its peers regarding revenues, profits, and invested capital. The stock price is higher than for 52% of alternative stocks in the same industry. The consolidated Safety Rank has a riskier rank of 26, which means that the company has a riskier financing structure than 74% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. The consolidated Sentiment Rank also has a low rank of 23, indicating professional investors are more pessimistic about the stock than for 77% of alternative investment opportunities. ...read more

more
Strongest Rank Dividend Yield
Weakest Rank Price vs. Earnings (P/E)
Country USA
Industry Life Sciences Tools & Services
Size Medium
Website 10xgenomics.com
Index
NASDAQ
10x Genomics stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 26-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
48 55 12 9
Growth
73 19 59 59
Safety
Safety
26 75 60 54
Sentiment
23 9 79 71
360° View
360° View
31 18 61 41
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
10 20 39 38
Opinions Change
34 6 50 50
Pro Holdings
n/a 8 65 69
Market Pulse
34 60 89 70
Sentiment
23 9 79 71
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
48 55 12 9
Growth
73 19 59 59
Safety Safety
26 75 60 54
Combined
49 44 40 28
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
46 61 11 9
Price vs. Earnings (P/E)
100 12 12 4
Price vs. Book (P/B)
31 53 12 6
Dividend Yield
1 1 1 1
Value
48 55 12 9
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
8 60 79 82
Profit Growth
45 36 21 91
Capital Growth
86 44 4 7
Stock Returns
93 7 91 33
Growth
73 19 59 59
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
77 100 100 100
Refinancing
40 63 33 31
Liquidity
6 1 12 7
Safety Safety
26 75 60 54

Similar Stocks

Discover high‑ranked alternatives to 10x Genomics and broaden your portfolio horizons.

Omnicom

NYQ:OMC
Country: USA
Industry: Advertising
Size: X-Large
Full Stock Analysis

ResMed

NYQ:RMD
Country: USA
Industry: Health Care Equipment
Size: X-Large
Full Stock Analysis

Aramark

NYQ:ARMK
Country: USA
Industry: Restaurants
Size: X-Large
Full Stock Analysis

FedEx

NYQ:FDX
Country: USA
Industry: Air Freight & Logistics
Size: XX-Large
Full Stock Analysis

Frequently Asked
Questions

The only positive is high growth. The stock is expensive (low Value Rank), risky to finance, and carries critical professional sentiment. This is a risky proposition. Avoid unless you have exceptional conviction that the growth alone will overcome the price and financial risks.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews